Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market

Two therapies are used for treatment of ITP in Middle East, and it is categorized into first-line therapy (Corticosteroids, intravenous immunoglobulin (IVIG), and anti-D immune globulin) and second-line therapy (thrombopoietin receptor agonists, monoclonal antibody). However, despite availability of these therapies, some patients still remain refractory to the treatment. The ongoing research for treatment of ITP is focused on combining therapies and addressing multiple mechanisms of the disease simultaneously. As per data published by the American Society of Hematology in July 2018, the emerging combination therapies for ITP treatment are the combination of drugs, dexamethasone and rituximab which has been examined in several trials and has been indicated to provide superior results to either drug as monotherapy in some patients, and the possibility to revert lymphocyte subset abnormalities commonly seen in active disease. The addition of cyclosporine to rituximab and dexamethasone has also been evaluated in small adult studies and has provided enduring remission in a subset of treated patients, without substantial reported toxicity. Market Dynamics Increasing prevalence of immune thrombocytopenic purpura in pediatric population is expected to drive growth of the immune thrombocytopenic purpura drugs market in Middle East and Turkey. For instance, according to data published by the Paediatric Blood Cancer journal in 2013, around 10% of children with acute immune thrombocytopenia purpura were admitted to hospitals in Egypt in 2013. The immune thrombocytopenic purpura drugs market growth in the Middle East and Turkey is expected to be hampered, owing to slower execution of rules and regulations regarding the approval and launch of treatment drugs compared to North America and Europe. For instance, in the Middle East, Amgen Inc.'s Nplate (romiplostim) is the only drug currently available for treatment of immune (idiopathic) thrombocytopenic purpura (ITP). This drug is present in the U.S. since 2003. Later in 2006, Amgen launched it in Israel, Kuwait, Egypt, and Lebanon. Key features of the study • This report provides in-depth analysis of the Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2026 – 2033, considering 2025 as the base year • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, country outlook, and competitive strategies adopted by leading players • It profiles key players in the Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies • Key players covered as a part of this study include Amgen Inc., Octapharma AG, Novartis AG, Swedish Orphan Biovitrum AB, and Rigel Pharmaceuticals, Inc. • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics • The Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs market, research and consulting firms, new entrants, and financial analysts Market Segmentation • Drug Type Insights (Revenue, USD Mn, 2026 - 2033) o Steroid o Immunoglobulins o Thrombopoietin Receptor Agonist o Others • Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • Country Insights (Revenue, USD Mn, 2026 - 2033) o Middle East  Turkey  GCC Countries  Israel  Rest of Middle East • Key Players Insights o Amgen Inc. o Octapharma AG o Novartis AG o Swedish Orphan Biovitrum AB o Rigel Pharmaceuticals, Inc.